Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP639246.RASVzETpwZ0zmkvMSRDv06LKYFJWG2YxXeQ7Hm6eI-MgY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP639246.RASVzETpwZ0zmkvMSRDv06LKYFJWG2YxXeQ7Hm6eI-MgY130_assertion type Assertion NP639246.RASVzETpwZ0zmkvMSRDv06LKYFJWG2YxXeQ7Hm6eI-MgY130_head.
- NP639246.RASVzETpwZ0zmkvMSRDv06LKYFJWG2YxXeQ7Hm6eI-MgY130_assertion description "[To determine if ovarian cancer patients would be suitable for MAGE-peptide vaccine-based immunotherapy, the frequency of expression of the MAGE-1-4 genes in ovarian tumours was assessed using reverse transcription polymerase chain reaction (RT-PCR) and product verification with digoxigenin-labelled oligonucleotide probes specific for each MAGE gene.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP639246.RASVzETpwZ0zmkvMSRDv06LKYFJWG2YxXeQ7Hm6eI-MgY130_provenance.
- NP639246.RASVzETpwZ0zmkvMSRDv06LKYFJWG2YxXeQ7Hm6eI-MgY130_assertion evidence source_evidence_literature NP639246.RASVzETpwZ0zmkvMSRDv06LKYFJWG2YxXeQ7Hm6eI-MgY130_provenance.
- NP639246.RASVzETpwZ0zmkvMSRDv06LKYFJWG2YxXeQ7Hm6eI-MgY130_assertion SIO_000772 9743307 NP639246.RASVzETpwZ0zmkvMSRDv06LKYFJWG2YxXeQ7Hm6eI-MgY130_provenance.
- NP639246.RASVzETpwZ0zmkvMSRDv06LKYFJWG2YxXeQ7Hm6eI-MgY130_assertion wasDerivedFrom befree-20140225 NP639246.RASVzETpwZ0zmkvMSRDv06LKYFJWG2YxXeQ7Hm6eI-MgY130_provenance.
- NP639246.RASVzETpwZ0zmkvMSRDv06LKYFJWG2YxXeQ7Hm6eI-MgY130_assertion wasGeneratedBy ECO_0000203 NP639246.RASVzETpwZ0zmkvMSRDv06LKYFJWG2YxXeQ7Hm6eI-MgY130_provenance.